Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 4 Proinflammatory immune cells and their crosstalk in patients with IBD Figure 4 | Proinflammatory immune cells and their crosstalk in patients.

Published byBaldric Hawkins Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 4 Proinflammatory immune cells and their crosstalk in patients with IBD Figure 4 | Proinflammatory immune cells and their crosstalk in patients."— Presentation transcript:

1 Figure 4 Proinflammatory immune cells and their crosstalk in patients with IBD
Figure 4 | Proinflammatory immune cells and their crosstalk in patients with IBD. Although IL-12-driven type 1 T helper (TH1) cells and IL-23-activated type 17 T helper (TH17) cells were detected in Crohn's disease, type 2 T helper (TH2), type 9 T helper (TH9) and TH17 cells were identified in ulcerative colitis. The key transcription factors for each T-cell subset as well as the subset associated signature cytokines are indicated. NK cell, natural killer cell; Treg cell, regulatory T cell. Neurath, M. F. (2016) Current and emerging therapeutic targets for IBD Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Download ppt "Figure 4 Proinflammatory immune cells and their crosstalk in patients with IBD Figure 4 | Proinflammatory immune cells and their crosstalk in patients."

Similar presentations

Regulatory T cells & parasites: therapeutic potential

Regulatory T cells & parasites: therapeutic potential
Figure 3 Low-grade inflammation in FGID

Figure 3 Low-grade inflammation in FGID
Figure 2 Exosome composition

Figure 2 Exosome composition
Figure 4 The gut microbiota directly influences T-cell differentiation

Figure 4 The gut microbiota directly influences T-cell differentiation
Figure 5 Dendritic cells in liver inflammation

Figure 5 Dendritic cells in liver inflammation
Figure 4 Activation of clopidogrel via cytochrome P450

Figure 4 Activation of clopidogrel via cytochrome P450
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 5 Therapeutic paradigms for interfering with the brain–gut axis

Figure 5 Therapeutic paradigms for interfering with the brain–gut axis
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 7 Treatment algorithm for perianal fistulizing disease

Figure 7 Treatment algorithm for perianal fistulizing disease
Figure 6 Injection of mesenchymal stem cells in perianal fistulas

Figure 6 Injection of mesenchymal stem cells in perianal fistulas
Figure 1 Patients cured of HCV infection

Figure 1 Patients cured of HCV infection
Figure 1 Gut microorganisms at the intersection of several diseases

Figure 1 Gut microorganisms at the intersection of several diseases
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 3 Natural and imatinib-induced immunosurveillance in gastrointestinal tumours (GISTs) Figure 3 | Natural and imatinib-induced immunosurveillance.

Figure 3 Natural and imatinib-induced immunosurveillance in gastrointestinal tumours (GISTs) Figure 3 | Natural and imatinib-induced immunosurveillance.
Figure 2 The microbiome–gut–brain axis

Figure 2 The microbiome–gut–brain axis
Figure 7 Clinical options for HCC therapy

Figure 7 Clinical options for HCC therapy
Figure 2 Main functions of IL-1

Figure 2 Main functions of IL-1
Figure 3 The T-cell cytokine tree in IBD

Figure 3 The T-cell cytokine tree in IBD
Figure 1 Organs involved in coeliac-disease-associated autoimmunity

Figure 1 Organs involved in coeliac-disease-associated autoimmunity

Similar presentations

Ads by Google